{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(9)"],"submitter":["Blasco A"],"funding":["GEICAM Spanish Breast Cancer Group"],"pubmed_abstract":["<h4>Importance and objective</h4>Several definitions of efficacy endpoints have been proposed for clinical trials in early breast cancer (EBC). Invasive disease-free survival (IDFS) and other endpoints have been used as surrogates for overall survival (OS) in adjuvant trials. The aim was to evaluate these endpoints in a comparative way in a large cohort of patients to assess whether they are appropriate surrogates for OS.<h4>Participants and design</h4>Individual patient data from 8 phase III randomized adjuvant chemotherapy (CT) trials for EBC were analyzed. Trial-level surrogacy analyses were conducted using weighted least squares regression to assess the association between treatment effects on surrogates at different time points-IDFS and other defined endpoints (by STEEP v2.0)-and OS. "],"journal":["The oncologist"],"pagination":["oyaf263"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12450318"],"repository":["biostudies-literature"],"pubmed_title":["Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials."],"pmcid":["PMC12450318"],"pubmed_authors":["Lopez-Tarruella S","Calvo L","Chan A","Urruticoechea A","Garcia-Saenz JA","Bermejo B","Pienkowski T","Ruiz-Borrego M","Slamon D","Herranz J","Spera G","Guerrero-Zotano A","Martin M","Chap L","Crown J","Semiglazov V","Carrasco E","Blasco A"],"additional_accession":[]},"is_claimable":false,"name":"Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.","description":"<h4>Importance and objective</h4>Several definitions of efficacy endpoints have been proposed for clinical trials in early breast cancer (EBC). Invasive disease-free survival (IDFS) and other endpoints have been used as surrogates for overall survival (OS) in adjuvant trials. The aim was to evaluate these endpoints in a comparative way in a large cohort of patients to assess whether they are appropriate surrogates for OS.<h4>Participants and design</h4>Individual patient data from 8 phase III randomized adjuvant chemotherapy (CT) trials for EBC were analyzed. Trial-level surrogacy analyses were conducted using weighted least squares regression to assess the association between treatment effects on surrogates at different time points-IDFS and other defined endpoints (by STEEP v2.0)-and OS. ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-29T03:22:36.2Z","creation":"2026-06-29T03:19:47.522Z"},"accession":"S-EPMC12450318","cross_references":{"pubmed":["40838872"],"doi":["10.1093/oncolo/oyaf263"]}}